中国中医眼科杂志2025，Vol.35Issue(6)：567-572,578,7.DOI:10.13444/j.cnki.zgzyykzz.2025.06.014
增殖性玻璃体视网膜病变的分子靶点及治疗进展
Molecular Targets and Therapeutic Advances in Proliferative Vitreoretinopathy
摘要
Abstract
Proliferative vitreoretinopathy(PVR)is one of the most complex and vision-threatening ocular diseases in clinical practice.It is the leading cause of failure in the surgical re-pair of rhegmatogenous retinal detachment(RRD)and a severe complication of posterior segment open-globe injuries.The hallmark of PVR is the formation of contractile fibrotic epiretinal and sub-retinal membranes composed primarily of proliferating fibroblasts and myofibroblasts.These mem-branes exert traction on the retina,leading to recurrent retinal detachment,progressive visual im-pairment,and even blindness,severely affecting surgical prognosis.This review summarizes the pathophysiology of PVR and its associated molecular targets,including key cytokines and growth factors.It also discusses the latest advances in both Western Medicine and Traditional Chinese Medicine(TCM)treatments.While surgical intervention remains the primary modality for PVR,pharmacological therapies—particularly Western medicines—show limited efficacy and pose cer-tain side effects.In contrast,TCM therapies are characterized by fewer adverse reactions and higher safety profiles and have demonstrated favorable clinical outcomes.These findings suggest that TCM may offer novel insights and complementary strategies for the clini-cal management of PVR.关键词
增殖性玻璃体视网膜病变/细胞因子/生长因子/治疗Key words
proliferative vitreoreti-nopathy/cytokines/growth factors/treat-ment分类
医药卫生引用本文复制引用
戴金辉,周晓容,曾梅艳,白海霞,彭清华,吴权龙..增殖性玻璃体视网膜病变的分子靶点及治疗进展[J].中国中医眼科杂志,2025,35(6):567-572,578,7.基金项目
1 国家自然科学基金项目(82004427)2 中医药防治眼耳鼻咽喉疾病湖南省重点实验室建设项目(2017TP1018)3 湖南省自然科学基金青年科学基金项目(2023JJ40474)4 湖南省中医药防治眼耳鼻咽喉疾病与视功能保护工程技术研究中心项目(2018TP2008)5 湖南省眼科疾病(中医)临床医学研究中心项目(2023SK4038) （82004427）
